R 7232Alternative Names: R7232
Latest Information Update: 23 Jul 2009
At a glance
- Originator Roche
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 16 Apr 2009 Discontinued - Phase-I for Hyperlipidaemia in Switzerland (unspecified route)